Please ensure Javascript is enabled for purposes of website accessibility

Is Moderna Stock a Buy?

By Adria Cimino - Mar 12, 2020 at 9:30AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Moderna’s coronavirus vaccine candidate boosted its shares, but efficacy data will determine its future growth prospects.

Amid the coronavirus outbreak, Moderna (MRNA 4.97%) has been making headlines as it works on a vaccine. The stock surged 28% during the Feb. 25 trading session after the biotech company announced the shipment of its vaccine candidate for a phase 1 study. The shares have climbed 55% from the start of the year to their peak earlier this month.

Strands of DNA carrying genetic instructions are shown against a green background.

Image source: Getty Images.

Since originating in China in January, the coronavirus has swept its way across the world racking up 118,000 cases so far. The crisis has shaken the stock market -- the S&P 500 has tumbled 15% since the start of the year -- as factory closures, quarantines, and travel warnings have halted activity across sectors. At the same time, investors have flocked to shares of companies like Moderna, which are working on vaccines or treatments to address the virus.

The power of mRNA

Now the question for the long-term investor is whether there is upside potential left in Moderna shares. Let's have a look at the company's technology and pipeline.

Moderna harnesses the power of messenger RNA (mRNA), which carries instructions from DNA to the part of our cells that produces the proteins our bodies need to function. Using mRNA, Moderna's investigative products give the body's cells instructions to make proteins that would prevent or treat disease.

Moderna has more than 20 candidates in the pipeline, including prophylactic vaccines to address Zika or cytomegalovirus (CMV), as well as therapeutic vaccines to treat diseases such as cancer. The size of Moderna's pipeline scores a lot of points for the company, but my concern is we don't yet know if the technology behind these candidates works in humans. Most of the programs are in phase 1 trials, which evaluate safety. In phase 2 trials, we begin to see efficacy findings in humans, but Moderna's phase 2 trials are ongoing.

Comments on efficacy

That said, there may be more data available to guide investors soon: Moderna said an initial phase 2 analysis of its CMV trial, evaluating safety and immunogenicity, will be reported in the third quarter. (CMV is a common virus that affects more than half of adults by age 40 and remains in the body -- but most healthy adults don't have symptoms or realize they carry the virus. It causes birth defects in babies who are infected.) Investors should be on the lookout for comments on efficacy in this phase 2 report or others in the future. Since Moderna's technology is based on instructing the body to make specific proteins, strong efficacy data for this method in one indication may be a positive sign for others.

Moderna faces competition from BioNTech SE (BNTX 5.63%) and CureVac, which both use mRNA-based technology for their programs. Like Moderna, their pipelines haven't yet passed the phase 2 stage in clinical development, so the race is on to see which company brings a product to market first. Moderna's coronavirus vaccine candidate may give it the upper hand as health authorities push to find treatments.

Is Moderna a buy?

It is either too late or too early to buy Moderna shares. Considering the stock's recent gains, those who already invested have benefited and may see more benefits if one or more of Moderna's programs is successful. For those who haven't yet bought Moderna shares, hold on before jumping aboard. Once the coronavirus panic subsides, it's likely share gains will be more moderate. And other candidates might represent more future revenue for Moderna than the coronavirus vaccine. Vaccines for epidemics and pandemics aren't necessarily the most lucrative areas for companies due to the short timeframe and the public pressure to set low prices.

Turning to the entire Moderna pipeline, data from various trials so far is encouraging, but it's best to wait and see if this biotech company's investigational products are efficacious in humans before betting on the shares.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Moderna, Inc. Stock Quote
Moderna, Inc.
MRNA
$149.95 (4.97%) $7.10
BioNTech SE Stock Quote
BioNTech SE
BNTX
$157.50 (5.63%) $8.40

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
316%
 
S&P 500 Returns
112%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 07/04/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.